Table 2.
Summary of medication exposure
| DLX (N=287) |
SSRIs
|
|||||
|---|---|---|---|---|---|---|
| Escitalopram (N=127) |
Sertraline (N=69) |
Paroxetine (N=47) |
Fluvoxamine (N=18) |
All SSRIs (N=261) |
||
| Doses in Japanese package insert, mg/day | ||||||
| Starting dose | 20 | 10 | 25 | 10–20 | 50 | – |
| Approved treatment dose | 40–60 | 10–20 | 25–100 | 20–40 | 50–150 | – |
| Maximum dose | 60 | 20 | 100 | 40 | 150 | – |
| Treatment period (days), mean (SD) | 74.8 (26.1) | 71.4 (25.9) | 76.0 (40.5) | 75.0 (23.6) | 72.2 (25.1) | 73.3 (30.0) |
| Dose (mg/day) at baseline | ||||||
| Mean (SD) | 20.6 (2.9) | 8.5 (2.4) | 30.4 (13.5) | 11.7 (4.2) | 47.2 (16.9) | – |
| Median | 20.0 | 10.0 | 25.0 | 10.0 | 50.0 | |
| Average dose (mg/day) | ||||||
| Mean (SD) | 29.7 (11.7) | 10.0 (3.6) | 47.3 (19.8) | 18.3 (7.0) | 68.1 (30.1) | – |
| Median | 25.2 | 10.0 | 46.3 | 19.1 | 64.8 | – |
Abbreviations: DLX, duloxetine; N, number of patients; SD, standard deviation; SSRIs, selective serotonin reuptake inhibitors.